Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6167-6177

  Christensen, Claus ^a   Ambartsumian, Noona ^a   Gilestro, Giorgio ^c   Thomsen, Birthe ^b   Comoglio, Paolo ^c   Tamagnone, Luca ^c   Guldberg, Per ^a   Lukanidin, Eugene ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; FURIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN P16; SEMAPHORIN; SEMAPHORIN 3E; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG METASTASIS; MOUSE; NERVE FIBER; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SOLID TUMOR;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; COS CELLS; DISEASE MODELS, ANIMAL; FEMALE; FURIN; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEURITES; PC12 CELLS; PROTEIN ISOFORMS; RATS; SEMAPHORINS;

EID: 22244475429     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4309     Document Type: Article

References (50)

1. Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol 1999;43:S3-10.
2. Paget S. The distribution of secondary growths in cancer of the breast (republication of Lancet 1889;1:571-3). Cancer Metastasis Rev 1989;8:98-101.
3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2002;3:453-8.
4. Chambers AP, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
5. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
6. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-7.
7. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100:10954-9.
8. Kang Y, Siegel PM, Shu W, et al. Multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
9. Semaphorin Nomenclature Committee. Unified nomenclature for the semaphorins/collapsins. Cell 1999;97:551-2.
10. Christensen CRL, Klingelhoefer J, Tarabykina S, Hulgaard EF, Kramerov D, Lukanidin E. Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. Cancer Res 1998;58:1238-44.
11. Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. Science 1996;274:1123-33.
12. Gitler AD, Lu MM, Epstein JA. PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. Dev Cell 2004;7:107-16.
13. Serini G, Valdembri D, Zanivan S, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003;424:391-7.
14. Park KW, Crouse D, Lee M, et al. The axonal attractant Netrin-1 is an angiogenic factor. Proc Natl Acad Sci U S A 2004;101:16210-5.
15. Wang B, Xiao Y, Ding BB, et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 2003;4:19-29.
16. Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res 2004;64:5212-24.
17. Giordano S, Corso S, Conrotto P, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002;4:720-4.
18. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin-1 mediates collapsin-1/Semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 1999;146:233-42.
19. Kessler O, Shraga-Heled N, Lange T, et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 2004;64:1008-15.
20. Sekido Y, Bader S, Latif F, et al. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A 1996;93:4120-5.
21. Tomizawa Y, Sekido Y, Kondo M, et al. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A 2001;98:13954-9.
22. Xiang R, Davalos AR, Hensel CH, Zhou XJ, Tse C, Naylor SL. Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res 2002;62:2637-43.
23. Bielenberg DR, Hida Y, Shimizu A, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 2004;114:1260-71.
24. Klosterman A, Lohrum M, Adams RH, Puschel AW. The chemorepulsive activity of the axonal guidance signal semaphorin D requires dimerization. J Biol Chem 1998;273:7326-31.
25. Koppel AM, Raper JA. Collapsin-1 covalently dimerizes, and dimerization is necessary for collapsing activity. J Biol Chem 1998;273:15708-13.
26. Adams RH, Lohrum M, Klosterman A, Betz H, Pueschel AW. The chemorepulsive activity of secreted semaphorins is regulated by Furin-dependent proteolytic processing. EMBO J 1997;16:6077-86.
27. Hamada J, Cavanaugh PG, Lotan O, Nicolson GL. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 1992;66:349-54.
28. Barberis D, Artigiani S, Casazza A. Plexin signaling hampers integrin-based adhesion, leading to Rho-kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility. FASEB J 2004;18:592-4.
29. Ambartsumian N, Christensen C, Lukanidin E. Endothelial cell invasion assay. In: Celis J, editor. Cell biology: a laboratory handbook, third ed. San Diego: Academic Press; 2005. In press.
30. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
31. Aslakson CJ, Rak JW, Miller BE, Miller FR. Differential influence of organ site on three subpopulations of a single mouse mammary tumor at two distinct steps in metastasis. Int J Cancer 1992;47:466-72.
32. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
33. O'Connell KA, Edidin M. A mouse lymphoid endothelial cell line immortalized by simian viras 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J Immunol 1990;144:521-5.
34. Sakai T, Furuyama T, Ohoka Y, et al. Mouse semaphorin H induces PC12 cell neurite outgrowth activating Ras-mitogen-activated protein kinase signaling pathway via Ca(2+) influx. J Biol Chem 1999;274:29666-71.
35. Taniguchi S, Iwamura T, Kitamura N, Yamanari H, Setoguchi T. Heterogeneities of attachment, chemotaxis, and protease production among clones with different metastatic potentials from a human pancreatic cancer cell line. Clin Exp Metastasis 1994;12:238-44.
36. Hill RP, Young SD, Cillo C, and Ling V. Metastatic cell phenotypes: quantitative studies using the experimental metastasis assay. Cancer Rev 1986;5:118-51.
37. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004;83:249-89.
38. Price JE. Metastasis from human breast cancer cell lines. Breast Cancer Res Treat 1996;39:93-102.
39. Phillips RA, Jewett MAS, Gallie BL. Growth of human tumors in immune-deficient SCID mice and nude mice. Curr Top Microbiol Immunol 1989;152:259-63.
40. Shtivelman E, Namikawa R. Species-specific metastasis of human tumor cells in the severe combined immunodeficiency mouse engrafted with human tissue. Proc Natl Acad Sci U S A 1995;92:4661-5.
41. LeCouter J, Lin R, Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002;8:913-7.
42. Gutman M, Singh RK, Xie K, Bucana CD, Fidler IJ. Regulation of IL-8 expression in human melanoma cells by the organ environment. Cancer Res 1995;55:2470-5.
43. Pozas E, Pascual M, Nguyen Ba-Charvet KT, et al. Age-dependent effects of secreted semaphorins 3A, 3F, and 3E on developing hippocampal axons: in vitro effects and phenotype of semaphorin 3A (-/-) mice. Mol Cell Neurosci 2001;18:26-43.
44. Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 1996;383:525-8.
45. Gu C, Rodriguez ER, Reimert DV, et al. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell 2003;5:45-57.
46. Tamagnone L, Comoglio PM. Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell Biol 2000;10:377-83.
47. Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, Shiu RP. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997;71:966-71.
48. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, Klein-Szanto AJ. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A 2001;98:10326-31.
49. Mbikay M, Sirois F, Yao J, Seidah NG, Chretien M. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 1997;75:1509-14.
50. Gu C, Yoshida Y, Livet J, Reimert DV, Mann F, Merte J. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005;307:265-8.